LMR Partners’s Palvella Therapeutics PVLA Stock Holding History

LMR Partners’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-289	Closed	-$89K	–	1231
2021 Q2	$89K	Buy	+289	New	+$63.4K	﹤0.01%	887

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LMR Partners's PVLA Position: Q3 2021 in Review

LMR Partners sold out of Palvella Therapeutics (PVLA) in Q3 2021, closing a stake of 289 shares — an estimated $89K sold.

LMR Partners first reported a position in PVLA in Q2 2021 and held it in 1 quarter. The position peaked at $89K in Q2 2021. 75 funds tracked by Wall St. Rank hold PVLA as of Q3 2021.

LMR Partners reported no remaining Palvella Therapeutics position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 289 Palvella Therapeutics shares in Q3 2021, an estimated $89K.
LMR Partners first reported a position in Palvella Therapeutics in Q2 2021 and held it in 1 quarter.
LMR Partners's Palvella Therapeutics position peaked at $89K in Q2 2021.
75 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.